AR and posterior cortical atrophy: Despite initial treatment response, unfortunately ATTs will ultimately fail in most PCa patients, and disease progresses to castrate-resistant PCa (CRPC) [3, 4] in which PCa cells have often adopted a number of complex resistance mechanisms, including AR amplification, mutation, or splice variants to maintain AR function in the low androgen environment [3, 5].